FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1095-1096 April 4, 2002 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Flanigan et al. (Dec. 6 issue)¹ provide evidence that nephrectomy can prolong survival in patients with metastatic renal-cell cancer who are treated with interferon alfa-2b. Although various mechanisms for the survival benefit can be postulated, one possibility not mentioned by the authors or the editorialist² is that some of the patients in the trial actually had localized, rather than metastatic, disease. Such patients would have had radiologic findings consistent with the presence of metastases, but the results of histologic examination would show that they were not metastatic lesions at all.

It would be valuable to know what . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.